Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Janneke E. Jaspers"'
Autor:
Janneke E. Jaspers, Jonathan F. Khan, William D. Godfrey, Andrea V. Lopez, Metamia Ciampricotti, Charles M. Rudin, Renier J. Brentjens
Publikováno v:
The Journal of Clinical Investigation, Vol 133, Iss 9 (2023)
Patients with small cell lung cancer (SCLC) generally have a poor prognosis and a median overall survival of only about 13 months, indicating the urgent need for novel therapies. Delta-like protein 3 (DLL3) has been identified as a tumor-specific cel
Externí odkaz:
https://doaj.org/article/1add364070234a5a9f42731c9c6e16d1
Autor:
Charles M. Rudin, Thales Papagiannakopoulos, John T. Poirier, Trudy G. Oliver, Triparna Sen, Mark T.A. Donoghue, Tyler Jacks, Elliot H. Akama-Garren, William M. Rideout, Andrea Ventura, Danilo Maddalo, Anastasia-Maria Zavitsanou, Janneke E. Jaspers, Francisco J. Sanchez-Rivera, Faruk E. Kombak, Kyle B. Spainhower, Parvathy Manoj, Viola Allaj, Emily A. Costa, Rebecca Caeser, Angeliki Karatza, Àlvaro Quintanal-Villalonga, Allison L. Richards, Triantafyllia Karakousi, Metamia Ciampricotti
Supplementary Figures S1 - S5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85e21dac3fbf8c8abfbd8d681c0ce639
https://doi.org/10.1158/2159-8290.22540609
https://doi.org/10.1158/2159-8290.22540609
Autor:
Sven Rottenberg, Jos Jonkers, Piet Borst, Shridar Ganesan, Mark J. O'Connor, Alan Lau, Niall M.B. Martin, Aaron Cranston, James H. Doroshow, Amal Aly, Jiuping Ji, Ellen Wientjens, Rinske Drost, Serge A. Zander, Liesbeth van Deemter, Wendy Sol, Ute Boon, Ariena Kersbergen, Janneke E. Jaspers
PDF file - 1.2MB, This file contains additional data on tumor responses to olaparib treatment (Fig. S1 and S2), pH2AX stainings on treated and untreated tumors (Fig. S3), analysis of mutations in 53BP1 (Fig. S4 and S7B), characterization of cell line
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a652d31d7f726c5046308e033b91f32
https://doi.org/10.1158/2159-8290.22528427.v1
https://doi.org/10.1158/2159-8290.22528427.v1
Autor:
Sven Rottenberg, Jos Jonkers, Piet Borst, Shridar Ganesan, Mark J. O'Connor, Alan Lau, Niall M.B. Martin, Aaron Cranston, James H. Doroshow, Amal Aly, Jiuping Ji, Ellen Wientjens, Rinske Drost, Serge A. Zander, Liesbeth van Deemter, Wendy Sol, Ute Boon, Ariena Kersbergen, Janneke E. Jaspers
PDF file - 86K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3083ab5ab5409d590292dfae49011f74
https://doi.org/10.1158/2159-8290.22528430
https://doi.org/10.1158/2159-8290.22528430
Autor:
Sven Rottenberg, Jos Jonkers, Piet Borst, Shridar Ganesan, Mark J. O'Connor, Alan Lau, Niall M.B. Martin, Aaron Cranston, James H. Doroshow, Amal Aly, Jiuping Ji, Ellen Wientjens, Rinske Drost, Serge A. Zander, Liesbeth van Deemter, Wendy Sol, Ute Boon, Ariena Kersbergen, Janneke E. Jaspers
Inhibition of PARP is a promising therapeutic strategy for homologous recombination–deficient tumors, such as BRCA1-associated cancers. We previously reported that BRCA1-deficient mouse mammary tumors may acquire resistance to the clinical PARP inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1b565e33bd781c3f96cd0231d55e631
https://doi.org/10.1158/2159-8290.c.6545711
https://doi.org/10.1158/2159-8290.c.6545711
Autor:
Sven Rottenberg, Jos Jonkers, Piet Borst, Shridar Ganesan, Mark J. O'Connor, Alan Lau, Niall M.B. Martin, Aaron Cranston, James H. Doroshow, Amal Aly, Jiuping Ji, Ellen Wientjens, Rinske Drost, Serge A. Zander, Liesbeth van Deemter, Wendy Sol, Ute Boon, Ariena Kersbergen, Janneke E. Jaspers
PDF file - 28K, Information on all antibodies and primers that were used in this study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::284cf015b81b108358519765025dbcca
https://doi.org/10.1158/2159-8290.22528421.v1
https://doi.org/10.1158/2159-8290.22528421.v1
Autor:
Charles M. Rudin, Thales Papagiannakopoulos, John T. Poirier, Trudy G. Oliver, Triparna Sen, Mark T.A. Donoghue, Tyler Jacks, Elliot H. Akama-Garren, William M. Rideout, Andrea Ventura, Danilo Maddalo, Anastasia-Maria Zavitsanou, Janneke E. Jaspers, Francisco J. Sanchez-Rivera, Faruk E. Kombak, Kyle B. Spainhower, Parvathy Manoj, Viola Allaj, Emily A. Costa, Rebecca Caeser, Angeliki Karatza, Àlvaro Quintanal-Villalonga, Allison L. Richards, Triantafyllia Karakousi, Metamia Ciampricotti
Small cell lung cancer (SCLC) has limited therapeutic options and an exceptionally poor prognosis. Understanding the oncogenic drivers of SCLC may help define novel therapeutic targets. Recurrent genomic rearrangements have been identified in SCLC, m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e119dfd0f00e496d01bd3fbdec93d54
https://doi.org/10.1158/2159-8290.c.6549427.v1
https://doi.org/10.1158/2159-8290.c.6549427.v1
Autor:
Mark J. O'Connor, Alan Lau, Keith W. Caldecott, Niall M.B. Martin, David Rudge, Jos Jonkers, Sven Rottenberg, Marina Pajic, Robert H. Bradbury, Attilla Ting, Bastiaan Evers, Charlotte Knights, Louise Jones, Janneke E. Jaspers, Henry Brown, Rajesh Odedra, Aaron N. Cranston, Stuart L. Rulten, Lenka Oplustil O'Connor
The PARP inhibitor AZD2461 was developed as a next-generation agent following olaparib, the first PARP inhibitor approved for cancer therapy. In BRCA1-deficient mouse models, olaparib resistance predominantly involves overexpression of P-glycoprotein
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2109b65c80b64c5dc8e0c07cc7793822
https://doi.org/10.1158/0008-5472.c.6508109
https://doi.org/10.1158/0008-5472.c.6508109
Autor:
Mark J. O'Connor, Alan Lau, Keith W. Caldecott, Niall M.B. Martin, David Rudge, Jos Jonkers, Sven Rottenberg, Marina Pajic, Robert H. Bradbury, Attilla Ting, Bastiaan Evers, Charlotte Knights, Louise Jones, Janneke E. Jaspers, Henry Brown, Rajesh Odedra, Aaron N. Cranston, Stuart L. Rulten, Lenka Oplustil O'Connor
Supplementary materials and methods. Suppl Table 1. MMS combination PF50 cell line assays. Concentration-dependent potentiation of MMS (PF50 ratios). Suppl Table 2. Permeability of AZD2461 and olaparib were assessed. Suppl Table 3. Activity of olapar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::730097b7c140c8178ff65dd44a170b76
https://doi.org/10.1158/0008-5472.22410926.v1
https://doi.org/10.1158/0008-5472.22410926.v1
Autor:
Piet Borst, Jos Jonkers, Sabine C. Linn, Lodewyk Wessels, Joost Gribnau, Michael M. Gottesman, Jean-Pierre Gillet, Jelle Wesseling, Eline van der Burg, Wendy Sol, Martin Lodén, Martijn Jonkers, Janneke E. Jaspers, Marina Pajic, Serge A.L. Zander, Ariena Kersbergen, Philip C. Schouten, Jorma de Ronde, Bas de Hoon, Marieke A. Vollebergh, Sven Rottenberg
PDF file - 44K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92b5fb59b68bb787b02c87bd4aebfbb7
https://doi.org/10.1158/0008-5472.22393901
https://doi.org/10.1158/0008-5472.22393901